Table 1 Baseline clinical and demographic characteristics

Age (y)

56.1 ± 13.5

55.6 ± 13.5

57.4 ± 13.7

0.335

Male gender (n, %)

130 (62.2)

98(62.8)

32 (60.4)

0.753

Body mass index (kg/m²)

26.5 ± 4.7

26.3 ± 4.5

27 ± 5.3

0.549

Tobacco use (n, %)

52 (24.8)

35 (28.8)

17(32)

0.281

Hypertension (n, %)

86 (41.1)

59 (37.8)

27 (50.9)

0.094

Diabetes (n, %)

16 (7.7)

9 (5.8)

7 (13.2)

0.079

Dyslipidemia (n, %)

75 (35.9)

55 (35.3)

20 (37.7)

0.747

History of heart failure (n, %)

6 (2.9)

4 (2.6)

2 (3.8)

0.651

Coronary artery disease (n, %)

15 (7.2)

10 (6.4)

5 (9.4)

0.464

History of TIA^a/CVA^b(n, %)

19 (9.1)

15 (9.6)

4 (7.5)

0.653

 Flecainide (n, %)

46 (22)

31(19.8)

15(28.3)

0.177

 Propafenone(n, %)

1(0.47)

0 (0)

1(1.8)

0.083

 Amiodarone(n, %)

9 (4.3)

6 (3.8)

3 (5.6)

0.555

 Sotalol (n, %)

24 (11.4)

16 (10.2)

8 (15)

0.316

 Metoprolol (n, %)

2 (0.9)

2 (1.2)

0 (0)

0.412

 Bisoprolol (n, %)

78 (37.3)

57 (36.5)

21 (39.6)

0.620

 Nebivolol (n, %)

6 (3.8)

5 (3.2)

1 (1.8)

0.632

ACE^c inhibitors before ablation

26 (12.4)

20 (12.8)

6 (11.3)

0.809

ARBs^d before ablation

11 (5.2)

9 (5.7)

2 (3.7)

0.592

Prior ablation

39 (18.6)

29 (18.5)

10 (18.8)

0.547

 - AVNRT^e

13 (6.2)

12 (7.7)

1 (1.9)

1.000

 - Right atrial flutter

13 (6.2)

8 (5.1)

5 (9.4)

1.000

 - AF^f

11 (5.3)

8 (5.1)

3 (5.7)

1.000

 - Other

2 (1.0)

1 (0.6)

1 (1.9)

1.000

CHA₂DS₂₋VAsc score

1.3 ± 1.4

1.2 ± 1.3

1.6 ± 1.7

0.134

Oral anticoagulation (n, %)

60 (28.7)

41 (26.3%)

19 (35.8%)

0.552

Aspirin (n, %)

23 (11)

17 (10.9)

6 (11.3)

0.874

Follow-up duration (months)

16.8 ± 6.3

16.9 ± 5.7

16.6 ± 7.7

0.795

Re-do ablation

31 (14.8)

0 (0)

31 (58.4)

–

 - Flecainide (n, %)

62 (29.6)

42 (26.9)

20 (37.7)

0.122

 - Propafenone (n, %)

2 (0.95)

1 (0.64)

1 (1.8)

0.415

 - Amiodarone (n, %)

9 (4.3)

6 (3.8)

3 (5.6)

0.561

 - Sotalol (n, %)

49 (23.4)

34 (21.8)

15 (28.3)

0.310

 - Metoprolol (n, %)

1(0.4)

1(0.6)

0 (0)

0.562

 - Bisoprolol (n, %)

111 (53.11)

81 (51.9)

30 (56.6)

0.497

 - Nebivolol (n, %)

4 (1.9)

4 (2.5)

0 (0)

0.241

 - ACE inhibitors (n, %)

27 (12.9)

21 (13.4)

6 (11.3)

0.710

 - ARBs (n, %)

6 (2.8)

6

0

0.150

 - Flecainide (n, %)

25 (11.9)

17 (10.8)

8 (15)

0.398

 - Propafenone (n, %)

2 (0.9)

0 (0)

2 (3.7)

0.060

 - Amiodarone (n, %)

6 (2.8)

3 (1.9)

3 (5.6)

0.154

 - Sotalol (n, %)

26 (12.4)

18 (11.5)

8 (15)

0.478

 - Metoprolol (n, %)

1 (0.4)

1(0.6)

0 (0)

0.562

 - Bisoprolol (n, %)

62 (29.6)

50 (23.9)

12 (22.6)

0.211

 - Nebivolol (n, %)

6 (2.8)

5 (3.2)

1 (1.8)

0.628

 - ACE inhibitors (n, %)

27 (12.9)

21 (13.4)

6 (11.3)

0.710

 - ARBs (n, %)

6 (2.8)

6

0

0.150

Recurrence in BP

8 (3.8)

0 (0)

8(15.1)

< 0.001